https://ramedapharma.com/a-look-inside-the-protein-bar/2020-05-18T09:32:35+00:00https://ramedapharma.com/unlocking-brain-secrets/2020-05-18T09:33:04+00:00https://ramedapharma.com/inteligent-transitions-in-ux-design/2019-07-18T15:22:19+00:00https://ramedapharma.com/tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e-acquires-a-large-generic-product-in-a-sizable-and-fast-growing-therapeutic-area/2020-05-18T15:28:18+00:00https://ramedapharma.com/rameda-commences-manufacture-of-anviziram-tablets-the-generic-equivalent-of-japanese-antiviral-avigan-for-treatment-of-covid-19-patients-and-receives-approval-from-egyptian-drug-auth/2021-02-04T14:05:22+00:00https://ramedapharma.com/rameda-launches-initiative-for-the-complementary-dispensary-and-home-delivery-of-medication-at-no-cost-underlining-its-dedication-to-ensuring-the-healthcare-and-safety-among-egypts-most-immu/2021-02-04T14:05:34+00:00https://ramedapharma.com/rameda-notified-of-anviziram-remdesivir-rameda-vial-prices-by-egyptian-drug-authority-on-track-to-market-first-remdesivir-rameda-production-in-september-2020/2021-02-04T14:03:13+00:00https://ramedapharma.com/tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e-s-chief-executive-officer-dr-amr-morsy-recognized-among-the-top-100-arabian-ceos-of-2020/2021-02-04T14:12:29+00:00https://ramedapharma.com/tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e-acquires-a-sizeable-molecule-in-a-fast-growing-therapeutic-area/2024-07-30T11:20:20+00:00https://ramedapharma.com/equinox-pharma-holding-limited-equinox-increases-its-stake-in-tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e/2024-07-30T11:38:00+00:00https://ramedapharma.com/rameda-reports-its-2q21-results/2024-07-30T11:39:15+00:00https://ramedapharma.com/rameda-reports-its-3q21-results/2024-07-30T11:48:29+00:00https://ramedapharma.com/rameda-reports-its-3q21-results-2/2024-07-30T11:49:34+00:00https://ramedapharma.com/equinox-pharma-holding-limited-equinox-alongside-other-investors-further-increases-its-stake-in-tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e/2024-07-30T11:50:09+00:00https://ramedapharma.com/rameda-reports-its-fy22-results/2024-07-30T11:50:45+00:00https://ramedapharma.com/rameda-reports-its-1q22-results/2024-07-30T11:51:34+00:00https://ramedapharma.com/rameda-partners-with-ifc-to-green-its-operations-in-egypt/2024-07-30T14:53:38+00:00https://ramedapharma.com/tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e-acquires-fast-growing-molecule-with-an-established-market-presence/2024-07-30T14:56:36+00:00https://ramedapharma.com/tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e-acquires-a-fast-growing-anticonvulsant-which-grew-at-2019-21-cagr-of-226/2024-07-30T14:57:14+00:00https://ramedapharma.com/tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e-commences-the-production-of-antiviral-covid-19-treatment-molnupiravir-rameda/2024-07-30T14:58:16+00:00https://ramedapharma.com/tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e-joins-the-un-global-compact-the-worlds-largest-corporate-sustainability-initiative/2024-07-30T14:58:52+00:00https://ramedapharma.com/tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e-inaugurates-a-new-high-precision-water-treatment-station/2024-07-30T14:59:26+00:00https://ramedapharma.com/rameda-reports-its-3q22-results/2024-07-30T15:00:17+00:00https://ramedapharma.com/rameda-reports-its-3q22-results-2/2024-07-30T15:00:50+00:00https://ramedapharma.com/rameda-acquires-exclusive-rights-for-the-distribution-and-marketing-of-physiomer-in-egypt/2024-07-30T15:01:34+00:00https://ramedapharma.com/rameda-reports-its-fy22-results-2/2024-07-30T15:02:02+00:00https://ramedapharma.com/rameda-reports-its-1q23-results/2024-07-30T15:03:02+00:00https://ramedapharma.com/tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e-finalizes-acquisition-of-a-portfolio-of-11-fast-growing-cardiometabolic-products/2024-07-30T15:03:35+00:00https://ramedapharma.com/rameda-reports-its-2q23-results/2024-07-30T15:04:13+00:00https://ramedapharma.com/equinox-pharma-holding-limited-equinox-increases-stake-in-tenth-of-ramadan-for-pharmaceutical-industries-and-diagnostic-reagents-rameda-s-a-e/2024-07-30T15:04:48+00:00https://ramedapharma.com/rameda-reports-its-3q23-results/2024-07-30T15:05:23+00:00https://ramedapharma.com/rameda-maintains-its-impressive-momentum-with-the-launch-of-a-new-type-2-diabetes-product-bolstering-its-chronic-portfolio/2024-07-30T15:05:52+00:00https://ramedapharma.com/rameda-4q23-earnings-release/2024-07-30T15:06:26+00:00https://ramedapharma.com/rameda-expands-freely-priced-portfolio-with-launch-of-ramelact-egypts-first-lactase-enzyme-supplement-for-the-treatment-of-lactose-intolerance/2024-07-30T15:06:51+00:00